Descripción de la empresa
Ventyx Biosciences Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the development of oral therapies designed for patients suffering from autoimmune, inflammatory, and neurodegenerative conditions. The company functions within the broader Healthcare sector, specifically targeting the Biotechnology industry, which implies a high level of scientific complexity and reliance on successful drug pipeline advancement to generate future value. As of the latest reported data, the entity holds a market capitalization of $1.00B and employs a workforce of 83 individuals. The combination of a $1.00B market cap with N/A reported revenue indicates that the company's valuation is currently derived primarily from asset backing, intellectual property, and clinical pipeline potential rather than established commercial sales, positioning it as a pre-commercialization biotech firm where equity value reflects future revenue expectations rather than current profit generation.
Salud financiera
Ventyx Biosciences Inc. reports N/A for revenue over the trailing twelve months (TTM), while the net income stands at -$106,607,000 and EBITDA is recorded at -$116,438,000. The absence of revenue paired with significant negative net income reveals a cost structure driven entirely by research and development expenditures and operational overheads, typical for clinical-stage entities attempting to advance assets through regulatory review. The company generates free cash flow of -$47,460,248, which signifies a continuous burn rate that consumes the company's liquid assets as it invests heavily in drug discovery and clinical trial infrastructure. All three margin metrics—gross margin, operating margin, and profit margin—are listed at 0.0%, a figure that reflects the lack of commercial sales and the fact that total costs currently exceed any potential revenue generation. Regarding balance sheet strength, the company holds $192.64M in cash against $10.02M in debt, resulting in a debt-to-equity ratio of 5.24, which indicates a highly leveraged capital structure relative to its equity base despite the substantial cash reserves. The current ratio is an exceptionally high 17.86, suggesting that short-term liquid assets significantly outweigh current liabilities, thereby providing ample liquidity to sustain operations without immediate refinancing risks. Return on Equity is -45.4% and Return on Assets is -28.5%, metrics that demonstrate how the current operational model consumes shareholder equity and assets through negative earnings rather than generating returns.
Evaluación de valoración
The valuation metrics for Ventyx Biosciences Inc. present a trailing P/E ratio of N/A due to the lack of positive earnings, while the forward P/E is listed as -8.94, implying that analysts project continued negative earnings in the near term. The price-to-book ratio is 5.22, indicating that the market values the company at more than five times its book value, a premium typically associated with high-growth biotech firms where intangible assets and pipeline potential are valued above their tangible book value. Alternative valuation measures such as the price-to-sales ratio (N/A) and EV/EBITDA (-7.01) further highlight the difficulty in applying traditional multiple-based valuation models to a company with no sales and negative earnings power. The stock has exhibited significant volatility, trading between a 52-week high of $25.00 and a 52-week low of $0.78. Based on the provided 52-week range, the current price sits at a level that reflects the substantial downside risk relative to the recent high, although the exact percentage below the high cannot be calculated without the current spot price, the proximity to the $0.78 low underscores the speculative nature of the security. The beta value is 1.27, which indicates that the stock's price volatility is 27% higher than the broader market, suggesting that price movements will likely be amplified during periods of market stress or sector-specific news.
Growth & Income
Ventyx Biosciences Inc. reports N/A for both revenue growth year-over-year and earnings growth year-over-year, reflecting the early-stage nature of the business where historical growth rates are not yet applicable. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, indicating that the firm retains all of its negative earnings to fund ongoing research and development activities rather than distributing income to shareholders. The company reinvests its entire capital base into advancing its pipeline of small molecule therapeutics for cardiometabolic disorders and neurodegenerative diseases rather than paying out distributions. The overall growth and income profile is characterized by a lack of current commercial traction, where the primary mechanism for value creation is the successful transition of clinical assets into marketable products rather than organic revenue expansion or dividend yield.